ArticleUpdates in surgery2026
Clinical progression and predictors of renal outcomes following liver transplantation: long-term follow-up results from a Taiwanese center.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal dysfunction post-liver transplant (LT) can escalate healthcare costs and mortality, yet remains under-studied. We retrospectively reviewed 393 consecutive adult liver recipients from 2004 to 2018 at one center, with longitudinal recording of estimated glomerular filtration rate (eGFR) pre- and post-LT. The outcomes encompassed post-LT mortality, new onset chronic kidney disease (CKD) stage 3 or higher, and progression of end stage renal disease (ESRD) among patients with pre-existing CKD. Cox regression analysis identified predictors of mortality and new-onset CKD stage 3 or higher. The multivariate analysis identified that post-LT eGFR < 60 mL/minute in the 1st year (HR = 1.94, 95% CI 1.164-3.233), P = 0.01), post-LT proteinuria in the 1st year (HR = 1.817, 95% CI 1.16-2.846, P < 0.01), hepatocellular carcinoma as LT cause (HR = 2.284, 95% CI 1.323-3.942, P < 0.01) and living donor graft (HR = 2.563, 95% CI 1.222-5.372, P = 0.01) were predictors for mortality. Cumulative incidences of new onset CKD stage 3 or higher at 1, 3, 5, 10, 15 years post-LT were 23.8%, 30.8%, 34.7%, 45.9%, 52.9%, respectively, and were associated with older age (HR = 1.035, 95% CI 1.012-1.059, P < 0.01), male sex (HR = 1.506, 95% CI 1.006-2.253, P = 0.047), pre-existing diabetes (HR = 1.533, 95% CI 1.092-2.207, P = 0.014), and pre-LT proteinuria (HR = 1.574, 95% CI 1.013-2.446, P = 0.044). The ESRD progression rates in pre-existing CKD recipients at 1, 3, 5, 7, 10 years post-LT were 8.7%, 18.8%, 28.8%, 33.9%, 51.9%, respectively. Significant cumulative incidences of new CKD stage 3 or higher and ESRD progression exists in LT recipients during long-term follow-up. Several mortality and renal dysfunction predictors were identified, emphasizing the need for early renal protection for liver recipients.
Indexed as
Identifiers
40810857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.